Twist Bioscience reports record Q2 revenue $75.3M (+25% YoY), raises FY2024 guidance

Twist Bioscience Corp

2024-Q2 EPS reported -$1.54 revenue$146,800,000

Record revenue $75.3M (+25% YoY); orders $93.2M (+45% YoY).
Net loss $45.5M ($0.79/sh) vs $59.2M ($1.04) YoY; adjusted EBITDA -$26.8M.
Gross margin improved to 41% from 31%; FY2024 revenue guidance raised to $300-304M, gross margin 41.5-42.0%.
Cash burn improved: net cash from ops -$42.4M H1FY24 vs -$98.4M; cash $293.3M.
NGS revenue $40.8M (+41% YoY), SynBio $29.8M (+23%), Biopharma $4.7M (-33%).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Twist Bioscience Corp reported fiscal year 2024 results: revenue $300M to $304M. Guidance raised.

Period: fiscal year 2024
Revenue: $300M to $304M
Guidance: raised
Result: guidance update

Exact text from the filing

— Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% —

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Twist Bioscience Corp reported fiscal second quarter ended March 31, 2024 results: revenue $75.3 million, net income -$45.5 million, EPS -$0.79.

Period: fiscal second quarter ended March 31, 2024
Revenue: $75.3 million
Net income: -$45.5 million
EPS: -$0.79
Result: reported results

Exact text from the filing

FISCAL 2024 SECOND QUARTER FINANCIAL RESULTS • Orders: Total orders received for the second quarter of fiscal 2024 increased to $93.2 million compared to $64.2 million for the same period of fiscal 2023 . • Revenue: Total revenues for the second quarter of fiscal 2024 increased to $75.3 million compared to $60.2 million for the same period of fiscal 2023 . ◦ SynBio revenue increased to $29.8 million for the second quarter of fiscal 2024 compared to $24.2 million for the same period of fiscal 2023. ◦ NGS revenue increased to $40.8 million for the second quarter of fiscal 2024 compared to $29.0 million for the same period of fiscal 2023. ◦ Biopharma revenue was $4.7 million for the second quarter of fiscal 2024 compared to $7.0 million in the same period of fiscal 2023. • Cost of Revenues: Cost of revenues for the second quarter of fiscal 2024 was $44.4 million compared to $41.7 million for the same period of fiscal 2023 . • Gross Margin: Gross margin for the second quarter of fiscal 202

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Twist Bioscience Corp filing history →

Source: SEC EDGAR

accession 0001628280-24-019999

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.